Madrid, Spain.
odor loss it is not just one of the factors diagnostic at the beginning of the year covid-19, is also a good prognostic symptom disease, according to an international survey conducted by scientists at the Universidad Complutense and the Hospital Clínico San Carlos in Madrid.
Through a study conducted in numerous centers, with the largest sample used so far (5,868 inpatients), the researchers confirmed that, although its origin is still a mystery, anosmia odor loss– can act as a good prognostic factor for the disease.
READ: The Netherlands suspends the use of the AstraZeneca vaccine due to concern
“It simply came to our notice then many implications, from the initial assessment of patients to the ability to understand the pathophysiology. Eventually, the invasion of the nasal epithelium causes the activation of a suitable immunity avoiding cytokine storms”, Explained Jesús Porta-Etessam, head of the Neurology Department of the Hospital Clínico San Carlos, professor at the Faculty of Medicine of the Complutense University of Madrid (UCM) and the first author of the paper.
Also: Florida can begin vaccinating the general public in April
In addition to identifying anosmia as a good prognostic factor, the researchers also found that olfactory and gustatory dysfunctions are more common in women (12.41% versus 8.67%) in those under 65 years of age. years and in patients with kidney, lung, cardiac, neurological or oncological pathologies.
Classify patients
The results obtained on one of symptoms the earliest coronavirus can serve as a criterion when classifying or taking patients therapeutic decisions, as the Complutense University of Madrid pointed out in a note published on Monday.
The conclusions of this study could be used to elaborate “Risk indices” complication, which, according to Porta-Etessam, would be very useful and interesting when observing, treating or evaluating discharge of patients.
In addition to UCM and the San Carlos Clinical Hospital, the Madrid hospitals in La Paz, Infanta Sofía, Nuestra Señora de América, Puerta de Hierro and Getafe also participated in the study; Clínico de Valladolid University Hospitals (northwestern Spain), Virgen de La Arraixaca (Murcia) -south-south-Álvaro Cunqueiro (Vigo) -nowest- and Burgos (north); Institute of Cardiology and Cardiovascular Surgery of Havana (Cuba); North Guayaquil General Hospital IESS Los Ceibos (Ecuador) or San Carlo Clinic in Milan (Italy). EFE